Home › Companies
All companies
264 clinical-stage companies. Search or filter to narrow the list.
| Ticker | Company | Therapeutic areas | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics | OphthalmologyRespiratory Rare | Phase 3 | $608M | 5 |
| AARD | Aardvark Therapeutics | DermatologyMetabolic+1 Rare | Phase 3 | $25.2M | 3 |
| ABVX | Abivax | Immunology | Phase 3 | $7.19B | 2 |
| ABSI | Absci | DermatologyGI/Hepatology+1 | Phase 1 | $1.31B | 6 |
| ACIU | AC Immune | Neurology Rare | Phase 3 | $210M | 11 |
| QUIT | Achieve Life Sciences | — | NDA Submitted | $673M | 2 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | Phase 2 | $536M | 7 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | Phase 2 | $61.4M | 9 |
| ACTU | Actuate Therapeutics | Oncology | Phase 2 | $15.2M | 4 |
| ABOS | Acumen Pharmaceuticals | Neurology | Phase 2 | $16.6M | 4 |
| ADAG | Adagene | Oncology | Phase 2 | $99.4M | 10 |
| ADCT | ADC Therapeutics | Oncology | Approved | $172M | 5 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | Phase 1 | $26.0M | 8 |
| ADMA | Adma Biologics | ImmunologyInfectious Disease Rare | Approved | $3.02B | 4 |
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | Approved | $1.79B | 7 |
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | Phase 2 | $292M | 4 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | Approved | $111M | 10 |
| AKTS | Aktis Oncology | Oncology | Phase 1 | $910M | 10 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | NDA Submitted | $41.9M | 5 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | Phase 2 | $256M | 10 |
| DRTS | Alpha Tau Medical | Oncology | Phase 2 | $1.12B | 6 |
| ATHE | Alterity Therapeutics | Neurology Rare | Phase 2 | $35.7M | 2 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | Phase 3 | $298M | 3 |
| ANRO | Alto Neuroscience | Neurology | Phase 2 | $999M | 6 |
| ALMS | Alumis | DermatologyImmunology+1 | Phase 3 | $628M | 5 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | Phase 3 | $3.54B | 5 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | Phase 2 | $161M | 6 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | Approved | $1.36B | 9 |
| ANIX | Anixa Biosciences | Oncology | Phase 1 | $92.8M | 3 |
| ANNX | Annexon | HematologyNeurology+2 Rare | Phase 3 | $662M | 6 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | Phase 2 | — | 9 |
| APVO | Aptevo Therapeutics | Oncology | Phase 1 | $1.6M | 8 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | Phase 3 | $2.36B | 8 |
| ARDX | Ardelyx | GI/HepatologyRenal | Approved | $799M | 4 |
| AVBP | ArriVent BioPharma | Oncology | Phase 3 | $553M | 7 |
| ARTV | Artiva Biotherapeutics | Oncology | Phase 1 | $191M | 6 |
| ARVN | Arvinas | NeurologyOncology Rare | Approved | $447M | 10 |
| ATAI | Atai Beckley | Neurology | Phase 2 | $2.73B | 5 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | Approved | $290M | 12 |
| AXSM | Axsome Therapeutics | Neurology Rare | Approved | $7.15B | 15 |
| BEAM | Beam Therapeutics | HematologyMetabolic+1 Rare | Phase 2 | $2.14B | 6 |
| BLTE | Belite Bio | MetabolicOphthalmology Rare | NDA Submitted | $6.35B | 6 |
| BCAX | Bicara Therapeutics | Oncology | Phase 2 | $637M | 4 |
| BCYC | Bicycle Therapeutics | Oncology | Phase 2 | $224M | 4 |
| BIOA | BioAge Labs | CardiovascularOphthalmology | Phase 2 | $234M | 2 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | Approved | $1.93B | 4 |
| BMEA | Biomea Fusion | MetabolicOncology | Phase 2 | $35.5M | 4 |
| BDTX | Black Diamond Therapeutics | Oncology | Phase 2 | $82.8M | 4 |
| BCTX | BriaCell Therapeutics | Oncology | Phase 3 | $30.7M | 8 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | Phase 1 | $156M | 6 |
| CCCC | C4 Therapeutics | Oncology | Phase 2 | $332M | 2 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | Phase 2 | $220M | 8 |
| CAMP | Camp4 Therapeutics | — | Phase 1 | $251M | 1 |
| CADL | Candel Therapeutics | Oncology | Phase 3 | $424M | 4 |
| CAPR | Capricor Therapeutics | Infectious DiseaseNeurology Rare | NDA Submitted | $489M | 2 |
| CRDL | Cardiol Therapeutics | Cardiovascular Rare | Phase 3 | $124M | 4 |
| CRBU | Caribou Biosciences | — | — | $36.8M | 0 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | Phase 3 | $187M | 4 |
| CLDX | Celldex Therapeutics | DermatologyImmunology+1 | Phase 3 | $2.20B | 6 |
| CLRB | Cellectar Biosciences | Oncology | Phase 2 | $9.2M | 7 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | Phase 1 | $249M | 9 |
| CRVO | CervoMed | Neurology Rare | Phase 2 | $22.7M | 4 |
| CGON | CG Oncology | Oncology | NDA Submitted | $7.05B | 1 |
| CMMB | Chemomab Therapeutics | GI/HepatologyImmunology+1 Rare | Phase 2 | $13.2M | 4 |
| CING | Cingulate | Neurology | NDA Submitted | $70.6M | 1 |
| CLNN | Clene | Neurology Rare | NDA Submitted | $46.4M | 5 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | Phase 2 | $574M | 8 |
| COGT | Cogent Biosciences | HematologyOncology Rare | NDA Submitted | $4.85B | 7 |
| CGTX | Cognition Therapeutics | Neurology | Phase 2 | $59.9M | 2 |
| CHRS | Coherus Oncology | Oncology | Approved | $74.0M | 5 |
| CMPS | COMPASS Pathways | Neurology | NDA Submitted | $1.13B | 3 |
| CMPX | Compass Therapeutics | Oncology | Phase 2 | $109M | 15 |
| CGEN | Compugen | Oncology | Phase 3 | $191M | 7 |
| CNTB | Connect Biopharma | Respiratory | Phase 2 | $37.3M | 4 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | Phase 2 | $375M | 4 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | Phase 3 | $858M | 7 |
| COYA | Coya Therapeutics | Neurology Rare | Phase 2 | $70.8M | 6 |
| CBIO | Crescent Biopharma | Oncology | Phase 2 | $507M | 10 |
| CRNX | Crinetics Pharmaceuticals | MetabolicOncology Rare | Approved | — | 6 |
| CUE | Cue Biopharma | ImmunologyOncology | Phase 2 | $23.7M | 6 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | NDA Submitted | $602M | 10 |
| CYDY | CytoDyn | NeurologyOncology | Phase 2 | $367M | 3 |
| CTMX | CytomX Therapeutics | Oncology | Phase 1 | $423M | 7 |
| DBVT | DBV Technologies | Immunology | NDA Submitted | $3.14B | 2 |
| DFTX | Definium Therapeutics | Neurology | Phase 3 | $4.02B | 4 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | Phase 3 | $3.49B | 9 |
| DYN | Dyne Therapeutics | MetabolicNeurology Rare | NDA Submitted | $3.00B | 10 |
| EWTX | Edgewise Therapeutics | Cardiovascular | Phase 2 | $4.60B | 3 |
| EIKN | Eikon Therapeutics | Oncology | Phase 2 | $279M | 13 |
| ELDN | Eledon Pharmaceuticals | ImmunologyMetabolic+1 Rare | Phase 2 | $167M | 3 |
| ELTX | Elicio Therapeutics | Oncology | Phase 2 | $40.5M | 6 |
| ELOX | Eloxx Pharmaceuticals | DermatologyRenal Rare | Phase 2 | $48.0M | 4 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | Approved | $253M | 8 |
| ELVN | Enliven Therapeutics | Oncology | Phase 1 | $3.45B | 1 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | Phase 2 | $522M | 4 |
| ERAS | Erasca | Oncology | Phase 1 | $4.87B | 5 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | Approved | $1.84B | 17 |
| EVMN | Evommune | DermatologyImmunology+1 | Phase 2 | $290M | 6 |
| EXEL | Exelixis | CardiovascularOncology | Approved | $16.7B | 23 |
| EYPT | EyePoint | Ophthalmology | Phase 3 | $34.1M | 2 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | Phase 2 | $124M | 10 |
| FHTX | Foghorn Therapeutics | Oncology | Preclinical | $110M | 4 |
| FBRX | Forte Biosciences | DermatologyGI/Hepatology | Phase 2 | — | 3 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | Approved | $61.4M | 16 |
| GUTS | Fractyl Health | Metabolic | Phase 3 | $12.8M | 1 |
| GANX | Gain Therapeutics | MetabolicNeurology Rare | Phase 1 | $52.5M | 5 |
| GNLX | Genelux | Oncology | Phase 3 | $96.1M | 3 |
| GERN | Geron | Oncology | Approved | $644M | 3 |
| GHRS | GH Research | NeurologyWomen's Health | Phase 2 | $1.25B | 4 |
| GOSS | Gossamer Bio | Cardiovascular Rare | NDA Submitted | $67.5M | 4 |
| GRCE | Grace Therapeutics | Neurology | NDA Submitted | $36.2M | 1 |
| GLSI | Greenwich LifeSciences | Oncology | Phase 3 | $274M | 1 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | Approved | $1.94B | 17 |
| HROW | Harrow | Ophthalmology Rare | Approved | $1.11B | 15 |
| HELP | Helus Pharma | Neurology | Phase 3 | $575M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | NDA Submitted | $2.65B | 15 |
| IMTX | Immatics | Oncology | Phase 3 | $958M | 8 |
| IMMX | Immix Biopharma | Hematology Rare | Phase 1 | $603M | 1 |
| IMRX | Immuneering | Oncology | Phase 3 | $224M | 5 |
| IMUX | Immunic | GI/HepatologyNeurology | Phase 3 | $116M | 4 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | Approved | $6.66B | 17 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | Approved | $1.44B | 12 |
| IMNM | Immunome | Oncology Rare | NDA Submitted | $2.03B | 9 |
| IMVT | Immunovant | ImmunologyNeurology Rare | Phase 3 | $6.87B | 4 |
| INAB | IN8bio | ImmunologyOncology | Phase 1 | $8.9M | 4 |
| IXHL | Incannex Healthcare | NeurologyRespiratory | Phase 2 | $21.8M | 2 |
| INBX | Inhibrx Biosciences | Oncology | NDA Submitted | $1.10B | 6 |
| INMB | Inmune Bio | Dermatology Rare | Phase 3 | $29.7M | 1 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | Approved | $26.7B | 15 |
| NTLA | Intellia Therapeutics | CardiovascularImmunology Rare | NDA Submitted | $1.37B | 3 |
| IVVD | Invivyd | Infectious Disease | Approved | $152M | 5 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | Approved | $4.49B | 29 |
| JBIO | Jade Biosciences | ImmunologyRenal Rare | Phase 2 | $1.07B | 4 |
| JANX | Janux Therapeutics | Oncology | Phase 1 | $655M | 4 |
| KAPA | Kairos Pharma | Oncology | Phase 2 | $1.9M | 12 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | Phase 2 | $60.7M | 13 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | Phase 3 | $222M | 5 |
| KPRX | Kiora Pharmaceuticals | Ophthalmology Rare | Phase 3 | $4.1M | 4 |
| KOD | Kodiak Sciences | Ophthalmology | Phase 3 | $6.33B | 8 |
| KURA | Kura Oncology | MetabolicOncology | Approved | $688M | 13 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | Phase 2 | $10.4B | 5 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | NDA Submitted | $297M | 6 |
| LRMR | Larimar Therapeutics | Neurology Rare | NDA Submitted | $313M | 1 |
| LBRX | LB Pharmaceuticals | Neurology | Phase 3 | $1.30B | 3 |
| LEGN | Legend Biotech | Oncology Rare | Approved | $3.12B | 17 |
| LENZ | LENZ Therapeutics | Ophthalmology | Approved | $110M | 1 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | Phase 2 | $236M | 12 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | Phase 2 | $207M | 13 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | Approved | $5.11B | 9 |
| LGVN | Longeveron | CardiovascularNeurology Rare | Phase 2 | $7.1M | 3 |
| MAIA | MAIA Biotechnology | Oncology | Phase 3 | $77.2M | 8 |
| MPLT | MapLight Therapeutics | Neurology | Phase 2 | $365M | 3 |
| MRKR | Marker Therapeutics | Oncology | Phase 1 | $14.0M | 5 |
| MAZE | Maze Therapeutics | MetabolicRenal Rare | Phase 2 | $1.80B | 4 |
| MBX | MBX Biosciences | Metabolic Rare | Phase 3 | $2.64B | 4 |
| MDNAF | Medicenna Therapeutics | Oncology | Phase 2 | $14.8M | 10 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | Phase 3 | $827M | 16 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | Approved | $1.54B | 5 |
| MIST | Milestone Pharmaceuticals | Cardiovascular | Approved | $51.4M | 2 |
| MLYS | Mineralys Therapeutics | CardiovascularRenal+1 | NDA Submitted | $1.28B | 3 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | Phase 2 | $47.7M | 8 |
| MBRX | Moleculin Biotech | Oncology | Phase 2 | $7.3M | 9 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | Phase 2 | $775M | 7 |
| MLTX | MoonLake Immunotherapeutics | DermatologyImmunology Rare | NDA Submitted | $957M | 4 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | Phase 3 | $1.23B | 11 |
| NGEN | NervGen Pharma | Neurology | Phase 3 | $211M | 3 |
| NGNE | Neurogene | Neurology Rare | Phase 3 | $478M | 1 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | Phase 2 | $2.9M | 3 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | NDA Submitted | $2.33B | 6 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | Phase 1 | $89.6M | 8 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | Phase 2 | $95.4M | 7 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | Approved | $109M | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | Phase 3 | $1.56B | 13 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | Phase 3 | $660M | 9 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | Phase 3 | $257M | 12 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | Phase 3 | $418M | 5 |
| OLMA | Olema Pharmaceuticals | Oncology | Phase 3 | $633M | 3 |
| OMER | Omeros | HematologyNeurology+2 Rare | Approved | $1.04B | 6 |
| ONCY | Oncolytics Biotech | Oncology | Phase 2 | $51.7M | 4 |
| OKUR | OnKure Therapeutics | Oncology | Preclinical | $104M | 2 |
| IRD | Opus Genetics | Ophthalmology Rare | Approved | $391M | 12 |
| ORIC | Oric Pharmaceuticals | Oncology | Phase 3 | $831M | 5 |
| ORKA | Oruka Therapeutics | DermatologyImmunology Rare | Phase 2 | $6.53B | 7 |
| OTLK | Outlook Therapeutics | Ophthalmology | Approved | $87.9M | 3 |
| OVID | Ovid Therapeutics | Neurology Rare | Phase 2 | $419M | 4 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 | Phase 3 | $9.5M | 5 |
| PALI | Palisade Bio | Immunology | Phase 2 | $181M | 3 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | Phase 1 | $16.0M | 4 |
| PEPG | PepGen | Neurology Rare | Phase 2 | $269M | 1 |
| CATX | Perspective Therapeutics | Oncology | Phase 1 | $104M | 5 |
| PHIO | Phio Pharmaceuticals | Oncology | Phase 1 | $8.6M | 4 |
| PMVP | PMV Pharmaceuticals | Oncology | Phase 2 | $92.2M | 7 |
| PYPD | PolyPid | Infectious DiseaseMetabolic+1 | NDA Submitted | $138M | 4 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | Phase 1 | $197M | 5 |
| PRLD | Prelude Therapeutics | HematologyOncology Rare | Phase 1 | $266M | 3 |
| PRME | Prime Medicine | GI/HepatologyRespiratory Rare | Phase 1 | $699M | 3 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | Phase 2 | $4.8M | 7 |
| PMN | ProMIS Neurosciences | Neurology Rare | Phase 1 | $28.9M | 9 |
| PRQR | ProQR Therapeutics | MetabolicNeurology Rare | Phase 1 | $163M | 7 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | Approved | $8.14B | 12 |
| TARA | Protara Therapeutics | DermatologyMetabolic+1 Rare | Phase 3 | $143M | 3 |
| QTTB | Q32 Bio | Dermatology | Phase 2 | $258M | 3 |
| QNRX | Quoin Pharmaceuticals | DermatologyImmunology Rare | Phase 2 | $236M | 4 |
| RAPP | Rapport Therapeutics | Neurology | Phase 3 | $1.41B | 6 |
| RXRX | Recursion Pharmaceuticals | Oncology | Phase 2 | $1.69B | 6 |
| RNTX | Rein Therapeutics | Respiratory Rare | Phase 2 | $30.7M | 1 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | Approved | $3.64B | 4 |
| RLMD | Relmada Therapeutics | MetabolicNeurology+1 Rare | Phase 2 | $321M | 4 |
| REPL | Replimune Group | Oncology | Approved | $1.87B | 5 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | Phase 3 | $4.7M | 11 |
| RVMD | Revolution Medicines | Oncology | Approved | $35.2B | 11 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | Approved | $8.08B | 14 |
| RCKT | Rocket Pharmaceuticals | CardiovascularImmunology Rare | Approved | $236M | 4 |
| SABS | SAB Biotherapeutics | Metabolic | Phase 2 | $266M | 1 |
| SGMT | Sagimet Biosciences | DermatologyMetabolic | Phase 3 | $709M | 3 |
| SANA | Sana Biotechnology | MetabolicOncology | Phase 1 | $563M | 4 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | Approved | $1.58B | 11 |
| SCYX | Scynexis | Infectious DiseaseRenal Rare | Approved | $28.4M | 5 |
| SLS | SELLAS Life Sciences Group | Oncology | Phase 3 | $3.90B | 9 |
| SEPN | Septerna | ImmunologyMetabolic+1 Rare | Phase 1 | $1.90B | 5 |
| SION | Sionna Therapeutics | Respiratory Rare | Phase 2 | $139M | 5 |
| SLDB | Solid Biosciences | CardiovascularNeurology Rare | Phase 3 | $695M | 6 |
| SPRB | Spruce Biosciences | Metabolic Rare | Preclinical | $116M | 2 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | Phase 2 | $8.91B | 10 |
| STOK | Stoke Therapeutics | Neurology Rare | Phase 3 | $1.73B | 2 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | Phase 3 | $3.90B | 5 |
| SMMT | Summit Therapeutics | Oncology | NDA Submitted | $8.53B | 6 |
| STRO | Sutro Biopharma | Oncology | Phase 1 | $148M | 3 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | Approved | $822M | 7 |
| TNGX | Tango Therapeutics | Oncology | Phase 1 | $3.75B | 5 |
| TSHA | Taysha Gene Therapies | Neurology Rare | Phase 3 | $1.30B | 4 |
| TECX | Tectonic Therapeutic | Cardiovascular Rare | Phase 2 | $401M | 4 |
| TLX | Telix Pharmaceuticals | Oncology | Approved | $3.01B | 25 |
| TENX | Tenax Therapeutics | Cardiovascular Rare | Phase 3 | $64.7M | 2 |
| TGTX | Tg Therapeutics | Neurology Rare | Approved | $9.48B | 6 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | Phase 2 | $83.2M | 5 |
| TVTX | Travere Therapeutics | MetabolicRenal Rare | Approved | $4.91B | 7 |
| HURA | TuHURA Biosciences | Oncology | Phase 3 | $92.1M | 4 |
| TTRX | Turn Therapeutics | DermatologyInfectious Disease Rare | Phase 2 | $261M | 4 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | Phase 2 | $1.35B | 5 |
| RARE | Ultragenyx Pharmaceutical | CardiovascularMetabolic+1 Rare | Approved | $1.70B | 10 |
| UNCY | Unicycive Therapeutics | Renal | NDA Submitted | $108M | 2 |
| QURE | uniQure | HematologyMetabolic+1 Rare | Approved | $1.46B | 4 |
| UPB | Upstream Bio | Respiratory | Phase 2 | $115M | 3 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | Approved | $230M | 27 |
| PCVX | Vaxcyte | Infectious Disease | Phase 3 | $9.40B | 7 |
| VERA | Vera Therapeutics | Infectious DiseaseRenal Rare | Approved | $1.89B | 6 |
| VSTM | Verastem | Oncology | Approved | $934M | 5 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology Rare | Approved | $53.9M | 4 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | Phase 3 | $3.43B | 9 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | Phase 3 | $1.58B | 6 |
| VRDN | Viridian Therapeutics | ImmunologyOphthalmology | Approved | $3.41B | 7 |
| VOR | Vor Biopharma | ImmunologyNeurology Rare | Phase 3 | $1.12B | 2 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | Phase 1 | $94.6M | 9 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | Phase 3 | $69.4M | 9 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | Phase 2 | $560M | 5 |
| XFOR | X4 Pharmaceuticals | — | Approved | $316M | 2 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | Approved | $2.59B | 28 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | NDA Submitted | $3.81B | 9 |
| XERS | Xeris Biopharma | MetabolicNeurology Rare | Approved | $3.07B | 4 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | NDA Submitted | $1.88B | 11 |
| ZNTL | Zentalis Pharmaceuticals | Oncology | Phase 3 | $146M | 1 |
| ZURA | Zura Bio | DermatologyImmunology Rare | Phase 2 | $99.7M | 4 |
| ZYME | Zymeworks | OncologyRespiratory | Approved | $1.78B | 12 |
No companies match those filters.